enGene
ENGN | NASDAQ
$1.89
-$0.52 (-21.58%)
At close: Nov 16, 2026, 4:00 PM ET
$1.94
+$0.05 (+2.65%)
After-hours:
Nov 16, 2026, 7:47 PM ET
enGene Company Profile
Company profile explainedCompany Profile
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer & Director |
| Joan Connolly | Chief Technology Officer |
| Amy Pott | Chief Global Commercialization Officer |
| Anthony T. Cheung | Consultant |
| Jill Buck | Chief Development Officer |
| Kathleen Richton | Senior VP of Finance, Principal Accounting & Financial Officer and Controller |
| Matthew Boyd | Chief Regulatory Officer |
| Tara Place | Senior Vice President of Human Resources |
| William J. Grossman | Interim Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | 4 | Filing |
| Sep 08, 2026 | 10-Q | Quarterly Report |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 22, 2026 | 3 | Filing |
enGene
| Country | Canada |
| IPO Date | Feb 1, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Ronald H. W. Cooper |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 29286X101 |
| ISIN Number | CA29286X1015 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ENGN